Free Trial

Editas Medicine (EDIT) News Today

Editas Medicine logo
$1.87 +0.22 (+13.33%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.88 +0.01 (+0.80%)
As of 09:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EDIT Latest News

Editas Medicine, Inc. stock logo
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has received an average recommendation of "Hold" from the fourteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eight have assigned a hold recom
Editas Medicine, Inc. stock logo
400,000 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Tang Capital Management LLC
Tang Capital Management LLC bought a new position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 400,000 shares of the company's stock, valued at approximately $5
Editas Medicine, Inc. stock logo
Jacobs Levy Equity Management Inc. Boosts Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)
Jacobs Levy Equity Management Inc. lifted its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 33.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 708,409 shares of the company's stock after acqu
Editas Medicine, Inc. stock logo
Robert W. Baird Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $4.00
Robert W. Baird cut their target price on Editas Medicine from $8.00 to $4.00 and set an "outperform" rating on the stock in a report on Tuesday.
Editas Medicine, Inc. stock logo
Editas Medicine, Inc. (NASDAQ:EDIT) Position Raised by Balyasny Asset Management L.P.
Balyasny Asset Management L.P. increased its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 647.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,3
Editas Medicine, Inc. stock logo
Stifel Financial Corp Decreases Stake in Editas Medicine, Inc. (NASDAQ:EDIT)
Stifel Financial Corp lessened its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 46.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 337,158 shares of the company's stock after selling 287,718 shares
Editas Medicine, Inc. stock logo
Raymond James Financial Inc. Makes New $303,000 Investment in Editas Medicine, Inc. (NASDAQ:EDIT)
Raymond James Financial Inc. bought a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 238,967 shares of the company's stock, v
Editas Medicine, Inc. stock logo
Wells Fargo & Company MN Sells 318,436 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)
Wells Fargo & Company MN trimmed its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 63.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,329 shares of the company's stock
Editas Medicine, Inc. stock logo
Editas Medicine (EDIT) to Release Quarterly Earnings on Wednesday
Editas Medicine (NASDAQ:EDIT) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-editas-medicine-inc-stock/)
Editas Medicine, Inc. stock logo
Susquehanna Fundamental Investments LLC Takes $346,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT)
Susquehanna Fundamental Investments LLC purchased a new position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 272,430 shares of the company's
Editas Medicine, Inc. stock logo
Zacks Research Raises Earnings Estimates for Editas Medicine
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at Zacks Research increased their FY2027 EPS estimates for Editas Medicine in a research report issued to clients and investors on Tuesday, April 29th. Zacks Research analyst A. Chakraborty now expects that the company will earn (
Editas Medicine, Inc. stock logo
Analysts Offer Predictions for Editas Medicine Q1 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Editas Medicine in a research note issued to investors on Monday, April 28th. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($0.55) per
Editas Medicine, Inc. stock logo
Editas Medicine (NASDAQ:EDIT) Upgraded by Cantor Fitzgerald to Strong-Buy Rating
Cantor Fitzgerald upgraded Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday.
Editas Medicine, Inc. stock logo
HC Wainwright Upgrades Editas Medicine (NASDAQ:EDIT) to Strong-Buy
HC Wainwright raised Editas Medicine to a "strong-buy" rating in a report on Monday.
Editas Medicine, Inc. stock logo
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from Analysts
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has earned a consensus rating of "Hold" from the fourteen ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating
Editas Medicine, Inc. stock logo
Renaissance Technologies LLC Acquires Shares of 1,451,049 Editas Medicine, Inc. (NASDAQ:EDIT)
Renaissance Technologies LLC bought a new position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,451,049 shares of the company's stock, valued at approximately $1,843,000. Re
Editas Medicine, Inc. stock logo
Leerink Partnrs Predicts Editas Medicine Q3 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Leerink Partnrs issued their Q3 2025 earnings per share estimates for Editas Medicine in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings per share of ($0.14) for
Editas Medicine, Inc. stock logo
Leerink Partnrs Forecasts Editas Medicine Q1 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Editas Medicine in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($0.46) for the
Editas Medicine, Inc. stock logo
238,967 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Raymond James Financial Inc.
Raymond James Financial Inc. purchased a new stake in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 238,967 shares of the company's stock, valued at approximately $303,00
Editas Medicine: Do The Risks Outweigh The Rewards?
Editas Medicine, Inc. stock logo
Zacks Research Comments on Editas Medicine FY2027 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Editas Medicine in a note issued to investors on Wednesday, March 26th. Zacks Research analyst A. Chakraborty expects that the company will post earn
Editas Medicine, Inc. stock logo
Editas Medicine (NASDAQ:EDIT) Share Price Passes Below 50 Day Moving Average - Here's Why
Editas Medicine (NASDAQ:EDIT) Stock Price Passes Below 50-Day Moving Average - Time to Sell?
Editas Medicine CFO Erick Lucera to step down, Amy Parison to succeed
Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

EDIT Media Mentions By Week

EDIT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EDIT
News Sentiment

0.75

0.87

Average
Medical
News Sentiment

EDIT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EDIT Articles
This Week

6

4

EDIT Articles
Average Week

Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:EDIT) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners